Capricor Therapeutics Inc (CAPR)
5.68
+0.13
(+2.34%)
USD |
NASDAQ |
May 31, 16:00
5.70
+0.02
(+0.35%)
After-Hours: 20:00
Capricor Therapeutics Enterprise Value: 140.77M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 31, 2024 | 140.77M |
May 30, 2024 | 136.64M |
May 29, 2024 | 138.23M |
May 28, 2024 | 154.13M |
May 24, 2024 | 150.63M |
May 23, 2024 | 153.18M |
May 22, 2024 | 158.90M |
May 21, 2024 | 160.18M |
May 20, 2024 | 160.50M |
May 17, 2024 | 157.31M |
May 16, 2024 | 139.50M |
May 15, 2024 | 129.64M |
May 14, 2024 | 125.50M |
May 13, 2024 | 133.14M |
May 10, 2024 | 127.56M |
May 09, 2024 | 131.36M |
May 08, 2024 | 129.78M |
May 07, 2024 | 132.62M |
May 06, 2024 | 134.83M |
May 03, 2024 | 132.94M |
May 02, 2024 | 125.67M |
May 01, 2024 | 128.51M |
April 30, 2024 | 126.62M |
April 29, 2024 | 128.51M |
April 26, 2024 | 131.04M |
Date | Value |
---|---|
April 25, 2024 | 122.82M |
April 24, 2024 | 119.35M |
April 23, 2024 | 112.40M |
April 22, 2024 | 116.19M |
April 19, 2024 | 118.40M |
April 18, 2024 | 119.66M |
April 17, 2024 | 135.46M |
April 16, 2024 | 147.47M |
April 15, 2024 | 145.26M |
April 12, 2024 | 157.58M |
April 11, 2024 | 156.95M |
April 10, 2024 | 159.16M |
April 09, 2024 | 168.64M |
April 08, 2024 | 168.01M |
April 05, 2024 | 172.44M |
April 04, 2024 | 171.80M |
April 03, 2024 | 174.96M |
April 02, 2024 | 177.81M |
April 01, 2024 | 184.29M |
March 31, 2024 | 174.65M |
March 28, 2024 | 174.42M |
March 27, 2024 | 173.79M |
March 26, 2024 | 159.30M |
March 25, 2024 | 169.38M |
March 22, 2024 | 161.50M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-4.972M
Minimum
Mar 10 2020
184.29M
Maximum
Apr 01 2024
59.45M
Average
58.94M
Median
Enterprise Value Benchmarks
Sarepta Therapeutics Inc | 12.12B |
PTC Therapeutics Inc | 2.190B |
Solid Biosciences Inc | 110.56M |
Inovio Pharmaceuticals Inc | 157.64M |
Stereotaxis Inc | 147.33M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -9.794M |
Revenue (Quarterly) | 4.907M |
Total Expenses (Quarterly) | 15.17M |
EPS Diluted (Quarterly) | -0.31 |
Profit Margin (Quarterly) | -199.6% |
Earnings Yield | -14.61% |
Normalized Earnings Yield | -15.72 |